Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
04 September 2023 - 3:00PM
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported
by Data Published in Brain
-
Landmark study shows mGlu5 receptor
negative allosteric modulators (NAMs)
restore lost
neurological functions
- First
time mGlu5 linked to
post-stroke
functional recovery
Ad Hoc Announcement Pursuant to
Art. 53 LR
Geneva, Switzerland,
September 4,
2023 - Addex
Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage
pharmaceutical company pioneering allosteric modulation-based drug
discovery and development, today announced that data published in
Brain demonstrating the potential therapeutic role of mGlu5
receptor negative allosteric modulators (NAMs) in facilitating
functional recovery following stroke supports the future
development of dipraglurant in post-stroke recovery. Dipraglurant
is a novel, orally available, highly selective mGlu5 NAM ready for
Phase 2 clinical studies, currently being evaluated in preclinical
models of post-stroke recovery.
“The role of the mGlu5 receptor in multiple
neurological indications and brain plasticity has been well
documented, however this is the first time that inhibition of this
receptor subtype has been linked to post-stroke functional
recovery,” said Mikhail Kalinichev, PhD, Head of Translational
Science at Addex. “We are very encouraged that the researchers
specifically evaluated mGlu5 NAMs, highlighting the significant
role this modality could play in the neural network recovery that
is vital for patients to regain function.”
Functional recovery following stroke relies on
the formation of new or reactivation of existing neural connections
while accumulating evidence suggests that the mGlu5 receptor
modulates brain plasticity and function. The researchers
investigated the influence of mGlu5 inhibition on this network
reorganization and functional recovery in preclinical models of
stroke. In the publication, titled “Inhibiting metabotropic
glutamate receptor 5 after stroke restores brain function and
connectivity”, the data showed that daily treatment with mGlu5 NAMs
for 12 days, starting 2 or 10 days after stroke, restored lost
somatosensory functions without diminishing infarct size. Within
hours of treatment, somatosensory recovery expressed in normalized
use of affected limbs, was apparent and progressed for the
subsequent 12 days. Functional recovery was prevented by activation
of mGlu5 with a positive allosteric modulator and accelerated in
mGlu5 knock-out mice. Furthermore, as measured by optical intrinsic
signal imaging, brain-wide disruptions in resting-state functional
connectivity after stroke were reversed by mGlu5 inhibition in
distinct sensorimotor cortices contralateral to the lesion and
bilaterally in visual cortices.
“This landmark paper supports our strategic
decision to evaluate dipraglurant in post-stroke recovery. There is
a huge unmet medical need for novel treatments to help stroke
patients recover, and there are currently no approved drugs that
promote functional recovery,” said Tim Dyer, CEO of Addex. “We
believe that dipraglurant is a strong candidate for future
development in post-stroke recovery based on its oral availability,
safe profile and selectivity toward the mGlu5 receptor.”
About Addex
Therapeutics: Addex Therapeutics is a
clinical-stage pharmaceutical company focused on the discovery and
development of an emerging class of novel orally available, small
molecule drugs known as allosteric modulators for neurological
disorders. Allosteric modulators offer several potential advantages
over conventional, non-allosteric molecules and may offer an
improved therapeutic approach to conventional "orthosteric" small
molecule or biological drugs. Addex's allosteric modulator drug
discovery platform targets receptors and other proteins that are
recognized as essential for therapeutic intervention. Addex's lead
drug candidate, ADX71149 (mGlu2 positive allosteric modulator or
PAM), developed in collaboration with Janssen Pharmaceuticals,
Inc., is in a Phase 2 clinical trial for the treatment of epilepsy.
Addex's second clinical program, dipraglurant (mGlu5 negative
allosteric modulator or NAM), is under preclinical evaluation for
future development in post-stroke recovery. Indivior PLC has
licensed Addex’s GABAB PAM program for the development of drug
candidates, with a focus on substance use disorder. Addex is also
advancing a broad preclinical pipeline, which includes development
of a range of GABAB PAMs for chronic cough, mGlu7 NAM for stress
related disorders, M4 PAM for schizophrenia and other forms of
psychosis and mGlu2 NAM for mild neurocognitive disorders and
depression. Addex shares are listed on the SIX Swiss Exchange and
American Depositary Shares representing its shares are listed on
the NASDAQ Capital Market, and trade under the ticker symbol "ADXN"
on each exchange.
Contacts:
Tim Dyer Chief Executive Officer Telephone: +41 22 884 15
55 PR@addextherapeutics.com |
Mike Sinclair Partner, Halsin Partners +44 (0)7968
022075 msinclair@halsin.com |
Addex Forward Looking
Statements: This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including
statements about the intended use of proceeds of the offering. The
words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release, are based on management's current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, uncertainties related to market conditions. These and
other risks and uncertainties are described in greater detail in
the section entitled “Risk Factors” in Addex Therapeutics’ Annual
Report on Form 20-F for the year ended December 31, 2022, as filed
with the SEC on March 30, 2023, the final prospectus supplement and
accompanying prospectus and other filings that Addex Therapeutics
may make with the SEC in the future. Any forward-looking statements
contained in this press release represent Addex Therapeutics’ views
only as of the date hereof and should not be relied upon as
representing its views as of any subsequent date. Addex
Therapeutics explicitly disclaims any obligation to update any
forward-looking statements.
Addex Therapeutics (LSE:0QNV)
Historical Stock Chart
From Apr 2024 to May 2024
Addex Therapeutics (LSE:0QNV)
Historical Stock Chart
From May 2023 to May 2024